How Much Is Your Company Worth?

Putting a value on how much an early-stage biotech company is worth is no easy task. Raising money for an early-stage biotech is even harder. But the good news is that last year was a record year for financing in the industry, with a 66 percent increase in VC funding over 2006, according a recently [...]

Opportunities Abound

Attendees awoke to the news this morning about GlaxoSmithKline’s announcement that it will pay millions — $720 million to be exact — for Sirtris Pharmaceuticals. This is the stuff biotech CEOs dream about. And it was the buzz at many breakfast tables at this morning’s workshop, “Antibiotics: Bad Bugs – Few Drugs.”
The BNVC meeting, of [...]

Standing Room Only

More than 60 company presentations are scheduled to take place between today and tomorrow. Whether you sat in on Optherion, Colby Pharmaceutical, or another presentation, chances are the session was jammed pack. Each presenter was allotted 15 minutes to make the case for why his or her company is the company to invest in. – [...]

BIO National Venture Conference Off to a Strong Start

While the economy may not be as robust as it has in recent years, there certainly was no sign of that at today’s Opening Luncheon. Jim Greenwood, our President & CEO welcomed attendees to the inaugural BIO National Venture Conference and cited these impressive stats:

140 top-level (VP and higher) venture capitalists – including 4 international investors – [...]

Welcome to Boston!

The marathon may be over, but that doesn’t mean there isn’t plenty more activity going on here in Boston.    We’re here in Cambridge, one of biotechnology’s “hot-spots” for the inaugural BIO National Venture Conference meeting up with some of the newest early stage and seed stage companies seeking venture funding.  Stay tuned for more as the [...]